概括
效应可以导致虚假低的免疫球蛋白A (IgA) 水平,可能掩盖多发性骨髓瘤. 稀释测试对于准确的IgA测量和诊断至关重要.
科学领域:
- 临床化学 临床化学
- 免疫学 免疫学 免疫学
- 诊断医学 诊断医学
背景情况:
- 免疫球蛋白A (IgA) 是免疫功能和多发性骨髓瘤诊断的关键生物标志物.
- 效应可以导致高度的虚假低IgA结果,掩盖疾病.
- 这种现象带来了误诊或错过诊断的风险.
研究的目的:
- 报告因效应导致IgA虚假降低的情况.
- 为了突出IgA测试中效应的临床意义.
- 为了强调准确的IgA量化的重要性.
主要方法:
- 一个案例研究报告了一名患有假降低IgA的患者.
- 对IgA,IgM和IgG水平以及血清环球蛋白的分析.
- 在序列稀释后重新测试样本,以确定真实的IgA度.
主要成果:
- 最初的IgA检测值为6.89g/L,明显低于血清环球蛋白水平 (52.5g/L).
- 稀释后的重新测试显示,真正的IgA值为37.25g/L.
- 这种差异证实了因效应引起的IgA虚假下降.
结论:
- IgA结果与血清环球蛋白水平之间的差异需要对效应进行调查.
- 实验室人员必须重新进行稀释测试,以获得准确的IgA水平.
- 准确的IgA测量对于防止误诊和错误诊断多发性骨髓瘤至关重要.
相关概念视频
Transcytosis of IgG
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Pneumonia I: Introduction
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Atypical Pneumonia
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia I: Introduction
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...


